Therapeutic improvement of adenomyosis by supramolecular cells-based macrophage membrane-encapsulated dydrogesterone nanoparticles via targeted drug delivery and inhibition of inflammation in the uterus
This study developed macrophage membrane-encapsulated dydrogesterone nanoparticles for targeted delivery to the uterus, showing therapeutic improvement of adenomyosis by inhibiting inflammation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (37)
- Adenomyosis: Mechanisms and Pathogenesis via openalex
- Adenomyosis pathogenesis: insights from next-generation sequencing via openalex
- Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence via openalex
- Conservative surgical treatment for adenomyosis: New options for looking beyond uterus removal via openalex
- Diagnosis, Evaluation, and Treatment of Adenomyosis via openalex
- Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model via openalex
- GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity via openalex
- How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic via openalex
- Immunological changes associated with adenomyosis: a systematic review via openalex
- Is adenomyosis an immune disease? via openalex
- Paris polyphylla ethanol extract and polyphyllin I ameliorate adenomyosis by inhibiting epithelial-mesenchymal transition via openalex
- Pathogenesis of uterine adenomyosis: invagination or metaplasia? via openalex
- Pathophysiology of adenomyosis via openalex
- Rhein ameliorates adenomyosis by inhibiting NF-κB and β-Catenin signaling pathway via openalex
- Round-the-clock or start-and-stop: Does the regimen matter when dydrogesterone is used to treat chronic pelvic pain due to endometriosis? via openalex
- Single-Cell Profiling Uncovers the Roles of Endometrial Fibrosis and Microenvironmental Changes in Adenomyosis via openalex
- Structural and molecular features of the endomyometrium in endometriosis and adenomyosis via openalex
- The distribution of immune cells and macrophages in the endometrium of women with recurrent reproductive failure. II: adenomyosis and macrophages via openalex
- The pathophysiology of endometriosis and adenomyosis: tissue injury and repair via openalex
- The place of dydrogesterone in the treatment of endometriosis and adenomyosis via openalex
- TIPE2 inhibits the migration and invasion of endometrial cells by targeting β-catenin to reverse epithelial–mesenchymal transition via openalex
- W3201778902 via openalex
- W3003671280 via openalex
- W4210367302 via openalex
- W4210694788 via openalex
- W4295780018 via openalex
- W4353079874 via openalex
- W3002305227 via openalex
- W4387640260 via openalex
- W2782685575 via openalex
- W2525448258 via openalex
- W4399264659 via openalex
- W4402622594 via openalex
- W4403154961 via openalex
- W4407694047 via openalex
- W3031854953 via openalex
- W4408786446 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00